AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ETON
  4. [8-K] Eton Pharmaceutcials, Inc. Reports Material Event

[8-K] Eton Pharmaceutcials, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose an auditor transition effective 13 June 2025.

Dismissal of Crowe LLP: The Audit Committee terminated Crowe LLP after only one audit cycle (FY-2024). Crowe鈥檚 2024 opinion was clean (no adverse or qualified opinion), and the firm reported no disagreements or reportable events with management under Item 304(a)(1) of Regulation S-K. Crowe鈥檚 required concurrence letter is attached as Exhibit 16.1.

Appointment of Grant Thornton LLP: The Audit Committee simultaneously engaged Grant Thornton LLP as the new independent registered public accounting firm for FY-2025. The company confirms that, during FY-2023, FY-2024, and the subsequent interim period, it did not consult Grant Thornton on any accounting matters or potential opinions prior to the appointment.

Investor takeaways:

  • The change appears procedural; the absence of disagreements reduces immediate red-flag risk.
  • Auditor turnover after one year may still prompt investors to monitor governance continuity and upcoming audit fees or timelines.
  • No financial restatements, outlook changes, or earnings data were disclosed in this filing.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) ha presentato un modulo 8-K per comunicare un cambio di revisore con effetto dal 13 giugno 2025.

Rimozione di Crowe LLP: Il Comitato di Revisione ha terminato il rapporto con Crowe LLP dopo un solo ciclo di revisione (anno fiscale 2024). L鈥檕pinione di Crowe per il 2024 猫 stata pulita (senza rilievi o opinioni qualificate) e la societ脿 non ha riscontrato disaccordi o eventi segnalabili con la direzione secondo l鈥橝rticolo 304(a)(1) del Regolamento S-K. La lettera di consenso richiesta da Crowe 猫 allegata come Documento 16.1.

Nomina di Grant Thornton LLP: Contemporaneamente, il Comitato di Revisione ha incaricato Grant Thornton LLP come nuovo revisore contabile indipendente per l鈥檃nno fiscale 2025. La societ脿 conferma che durante gli anni fiscali 2023, 2024 e il periodo intermedio successivo, non ha consultato Grant Thornton su questioni contabili o potenziali opinioni prima della nomina.

Considerazioni per gli investitori:

  • Il cambiamento sembra di natura procedurale; l鈥檃ssenza di disaccordi riduce il rischio di segnali d鈥檃llarme immediati.
  • Il cambio di revisore dopo un anno potrebbe comunque spingere gli investitori a monitorare la continuit脿 della governance e le future spese o tempistiche di revisione.
  • Non sono state comunicate rettifiche finanziarie, variazioni delle previsioni o dati sugli utili in questa comunicazione.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) present贸 un Formulario 8-K para informar una transici贸n de auditor efectiva a partir del 13 de junio de 2025.

Despido de Crowe LLP: El Comit茅 de Auditor铆a termin贸 la relaci贸n con Crowe LLP tras solo un ciclo de auditor铆a (a帽o fiscal 2024). La opini贸n de Crowe para 2024 fue limpia (sin opiniones adversas o calificadas), y la firma report贸 ning煤n desacuerdo ni eventos reportables con la administraci贸n seg煤n el 铆tem 304(a)(1) del Reglamento S-K. La carta de conformidad requerida de Crowe est谩 adjunta como Anexo 16.1.

Nombramiento de Grant Thornton LLP: El Comit茅 de Auditor铆a contrat贸 simult谩neamente a Grant Thornton LLP como la nueva firma de auditor铆a independiente registrada para el a帽o fiscal 2025. La compa帽铆a confirma que durante los a帽os fiscales 2023, 2024 y el periodo interino posterior, no consult贸 a Grant Thornton sobre asuntos contables o posibles opiniones antes del nombramiento.

Conclusiones para los inversores:

  • El cambio parece ser procedimental; la ausencia de desacuerdos reduce el riesgo inmediato de se帽ales de alerta.
  • El cambio de auditor tras un a帽o puede llevar a los inversores a vigilar la continuidad en la gobernanza y las pr贸ximas tarifas o plazos de auditor铆a.
  • No se divulgaron reexpresiones financieras, cambios en las perspectivas ni datos de ganancias en este documento.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON)鞚� 2025雲� 6鞗� 13鞚茧秬韯� 氚滍毃霅橂姅 臧愳偓鞚� 甑愳泊毳� 瓿奠嫓頃橁赴 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟.

Crowe LLP 頃挫瀯: 臧愳偓鞙勳洂須岆姅 雼� 頃� 氩堨潣 臧愳偓 欤缄赴(FY-2024) 頉� Crowe LLP鞕�鞚� 瓿勳暯鞚� 膦呺頄堨姷雼堧嫟. Crowe鞚� 2024雲� 鞚橁铂鞚� 鞝侅爼鞚挫棃鞙茧┌(攵�鞝曥爜 霕愲姅 頃滌爼 鞚橁铂 鞐嗢潓), 須岇偓電� 瓴届榿歆勱臣 甏�霠晿鞐� 攴滌爼 S-K 頃 304(a)(1) 頃橃棎 鞚搓铂鞚措倶 氤搓碃 雽�靸� 靷贝鞚� 鞐嗠嫟瓿� 氤搓碃頄堨姷雼堧嫟. Crowe鞚� 霃欖潣靹滉皜 歃濌卑鞛愲 16.1搿� 觳秬霅橃柎 鞛堨姷雼堧嫟.

Grant Thornton LLP 靹犾瀯: 臧愳偓鞙勳洂須岆姅 霃欖嫓鞐� Grant Thornton LLP毳� 2025 須岅硠鞐半弰 鞁犼窚 霃呺 霌彪 瓿奠澑須岅硠氩曥澑鞙茧 靹犾瀯頄堨姷雼堧嫟. 須岇偓電� 2023, 2024 須岅硠鞐半弰 氚� 鞚错泟 欷戧皠 旮瓣皠 霃欖晥 Grant Thornton瓿� 須岅硠 氍胳牅雮� 鞛犾灛鞝� 鞚橁铂鞐� 雽�頃� 靸侂嫶頃橃 鞎婌晿雼�瓿� 頇曥澑頄堨姷雼堧嫟.

韴瀽鞛� 彀戈碃 靷暛:

  • 鞚措矆 氤�瓴届潃 鞝堨皑鞝侅澑 靹标博鞙茧 氤挫澊氅�, 鞚搓铂鞚� 鞐嗠嫟電� 鞝愳潃 歃夑皝鞝侅澑 鞙勴棙 鞁犿樃毳� 雮顶雼堧嫟.
  • 1雲� 毵岇潣 臧愳偓鞚� 甑愳泊電� 韴瀽鞛愲摛鞚� 瓯半矂雱岇姢 鞐办啀靹标臣 頄ロ泟 臧愳偓 牍勳毄 霕愲姅 鞚检爼鞐� 雽�頃� 欤检嫓頃橁矊 頃� 靾� 鞛堨姷雼堧嫟.
  • 氤� 瓿奠嫓鞐愳劀電� 鞛 鞛瀾靹�, 鞝勲 氤�瓴�, 靾橃澋 雿办澊韯瓣皜 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Eton Pharmaceuticals, Inc. (NASDAQ : ETON) a d茅pos茅 un formulaire 8-K pour annoncer une transition d鈥檃uditeur effective au 13 juin 2025.

Renvoi de Crowe LLP : Le comit茅 d鈥檃udit a mis fin 脿 sa collaboration avec Crowe LLP apr猫s un seul cycle d鈥檃udit (exercice 2024). L鈥檕pinion de Crowe pour 2024 茅tait sans r茅serve (aucune opinion d茅favorable ou qualifi茅e), et la soci茅t茅 n鈥檃 signal茅 aucun d茅saccord ni 茅v茅nement 脿 d茅clarer avec la direction selon l鈥檃rticle 304(a)(1) du r猫glement S-K. La lettre de consentement requise de Crowe est jointe en annexe 16.1.

Nomination de Grant Thornton LLP : Le comit茅 d鈥檃udit a simultan茅ment engag茅 Grant Thornton LLP comme nouveau cabinet d鈥檃udit ind茅pendant pour l鈥檈xercice 2025. La soci茅t茅 confirme que, durant les exercices 2023, 2024 et la p茅riode int茅rimaire suivante, elle n鈥檃 pas consult茅 Grant Thornton sur des questions comptables ou d鈥櫭﹙entuelles opinions avant la nomination.

脌 retenir pour les investisseurs :

  • Ce changement semble de nature proc茅durale ; l鈥檃bsence de d茅saccords r茅duit le risque de signaux d鈥檃lerte imm茅diats.
  • Un changement d鈥檃uditeur apr猫s un an peut n茅anmoins inciter les investisseurs 脿 surveiller la continuit茅 de la gouvernance ainsi que les futurs frais ou d茅lais d鈥檃udit.
  • Aucune r茅vision financi猫re, changement de perspectives ou donn茅es de r茅sultats n鈥檃 茅t茅 divulgu茅 dans ce d茅p么t.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) hat ein Formular 8-K eingereicht, um einen Wechsel des Abschlusspr眉fers mit Wirkung zum 13. Juni 2025 bekannt zu geben.

K眉ndigung von Crowe LLP: Der Pr眉fungsausschuss hat Crowe LLP nach nur einem Pr眉fungszyklus (Gesch盲ftsjahr 2024) entlassen. Die Meinung von Crowe f眉r 2024 war 耻苍别颈苍驳别蝉肠丑谤盲苍办迟 (keine negativen oder eingeschr盲nkten Meinungen), und das Unternehmen berichtete unter Punkt 304(a)(1) der Regulation S-K keine Meinungsverschiedenheiten oder meldepflichtigen Ereignisse mit dem Management. Das erforderliche Einvernehmen von Crowe ist als Anlage 16.1 beigef眉gt.

Ernennung von Grant Thornton LLP: Der Pr眉fungsausschuss hat gleichzeitig Grant Thornton LLP als neue unabh盲ngige Wirtschaftspr眉fungsgesellschaft f眉r das Gesch盲ftsjahr 2025 beauftragt. Das Unternehmen best盲tigt, dass es im Gesch盲ftsjahr 2023, 2024 und im anschlie脽enden Zwischenzeitraum keine Beratung von Grant Thornton zu buchhalterischen Fragen oder m枚glichen Meinungen vor der Ernennung eingeholt hat.

F眉r Investoren wichtig:

  • Die 脛nderung erscheint prozedural; das Fehlen von Meinungsverschiedenheiten mindert unmittelbare Warnsignale.
  • Ein Wechsel des Abschlusspr眉fers nach einem Jahr k枚nnte Investoren dennoch dazu veranlassen, die Kontinuit盲t der Governance sowie k眉nftige Pr眉fungsgeb眉hren oder -fristen zu beobachten.
  • In dieser Meldung wurden keine finanziellen Neubewertungen, Prognose盲nderungen oder Gewinnzahlen offengelegt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine auditor switch; no reported conflicts, modest governance flag.

A one-year auditor tenure is uncommon and warrants monitoring, but the company鈥檚 detailed disclosure鈥攁ffirming no disagreements, clean prior opinion, and inclusion of Crowe鈥檚 consent letter鈥攁ligns with best practices under Item 304. Grant Thornton is a Top-10 audit firm, potentially offering deeper industry knowledge and internal-control expertise. Because there are no adverse opinions or unresolved issues, the event is largely neutral for shareholder risk. Investors should review the 2025 audit fee schedule and ensure timely issuance of next year鈥檚 10-K to confirm a smooth transition.

TL;DR: Neutral financial impact; watch for transition costs.

This 8-K contains no earnings revisions, guidance changes, or capital-market actions. Historically, auditor changes do not affect valuation unless tied to accounting disputes, which management states do not exist. Potential incremental costs from switching to Grant Thornton are unlikely to be material for Eton鈥檚 market cap. Still, quick auditor turnover can cause modest investor uncertainty until the first Grant Thornton opinion is issued. Overall, I assess limited share-price impact barring future disclosures.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) ha presentato un modulo 8-K per comunicare un cambio di revisore con effetto dal 13 giugno 2025.

Rimozione di Crowe LLP: Il Comitato di Revisione ha terminato il rapporto con Crowe LLP dopo un solo ciclo di revisione (anno fiscale 2024). L鈥檕pinione di Crowe per il 2024 猫 stata pulita (senza rilievi o opinioni qualificate) e la societ脿 non ha riscontrato disaccordi o eventi segnalabili con la direzione secondo l鈥橝rticolo 304(a)(1) del Regolamento S-K. La lettera di consenso richiesta da Crowe 猫 allegata come Documento 16.1.

Nomina di Grant Thornton LLP: Contemporaneamente, il Comitato di Revisione ha incaricato Grant Thornton LLP come nuovo revisore contabile indipendente per l鈥檃nno fiscale 2025. La societ脿 conferma che durante gli anni fiscali 2023, 2024 e il periodo intermedio successivo, non ha consultato Grant Thornton su questioni contabili o potenziali opinioni prima della nomina.

Considerazioni per gli investitori:

  • Il cambiamento sembra di natura procedurale; l鈥檃ssenza di disaccordi riduce il rischio di segnali d鈥檃llarme immediati.
  • Il cambio di revisore dopo un anno potrebbe comunque spingere gli investitori a monitorare la continuit脿 della governance e le future spese o tempistiche di revisione.
  • Non sono state comunicate rettifiche finanziarie, variazioni delle previsioni o dati sugli utili in questa comunicazione.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) present贸 un Formulario 8-K para informar una transici贸n de auditor efectiva a partir del 13 de junio de 2025.

Despido de Crowe LLP: El Comit茅 de Auditor铆a termin贸 la relaci贸n con Crowe LLP tras solo un ciclo de auditor铆a (a帽o fiscal 2024). La opini贸n de Crowe para 2024 fue limpia (sin opiniones adversas o calificadas), y la firma report贸 ning煤n desacuerdo ni eventos reportables con la administraci贸n seg煤n el 铆tem 304(a)(1) del Reglamento S-K. La carta de conformidad requerida de Crowe est谩 adjunta como Anexo 16.1.

Nombramiento de Grant Thornton LLP: El Comit茅 de Auditor铆a contrat贸 simult谩neamente a Grant Thornton LLP como la nueva firma de auditor铆a independiente registrada para el a帽o fiscal 2025. La compa帽铆a confirma que durante los a帽os fiscales 2023, 2024 y el periodo interino posterior, no consult贸 a Grant Thornton sobre asuntos contables o posibles opiniones antes del nombramiento.

Conclusiones para los inversores:

  • El cambio parece ser procedimental; la ausencia de desacuerdos reduce el riesgo inmediato de se帽ales de alerta.
  • El cambio de auditor tras un a帽o puede llevar a los inversores a vigilar la continuidad en la gobernanza y las pr贸ximas tarifas o plazos de auditor铆a.
  • No se divulgaron reexpresiones financieras, cambios en las perspectivas ni datos de ganancias en este documento.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON)鞚� 2025雲� 6鞗� 13鞚茧秬韯� 氚滍毃霅橂姅 臧愳偓鞚� 甑愳泊毳� 瓿奠嫓頃橁赴 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟.

Crowe LLP 頃挫瀯: 臧愳偓鞙勳洂須岆姅 雼� 頃� 氩堨潣 臧愳偓 欤缄赴(FY-2024) 頉� Crowe LLP鞕�鞚� 瓿勳暯鞚� 膦呺頄堨姷雼堧嫟. Crowe鞚� 2024雲� 鞚橁铂鞚� 鞝侅爼鞚挫棃鞙茧┌(攵�鞝曥爜 霕愲姅 頃滌爼 鞚橁铂 鞐嗢潓), 須岇偓電� 瓴届榿歆勱臣 甏�霠晿鞐� 攴滌爼 S-K 頃 304(a)(1) 頃橃棎 鞚搓铂鞚措倶 氤搓碃 雽�靸� 靷贝鞚� 鞐嗠嫟瓿� 氤搓碃頄堨姷雼堧嫟. Crowe鞚� 霃欖潣靹滉皜 歃濌卑鞛愲 16.1搿� 觳秬霅橃柎 鞛堨姷雼堧嫟.

Grant Thornton LLP 靹犾瀯: 臧愳偓鞙勳洂須岆姅 霃欖嫓鞐� Grant Thornton LLP毳� 2025 須岅硠鞐半弰 鞁犼窚 霃呺 霌彪 瓿奠澑須岅硠氩曥澑鞙茧 靹犾瀯頄堨姷雼堧嫟. 須岇偓電� 2023, 2024 須岅硠鞐半弰 氚� 鞚错泟 欷戧皠 旮瓣皠 霃欖晥 Grant Thornton瓿� 須岅硠 氍胳牅雮� 鞛犾灛鞝� 鞚橁铂鞐� 雽�頃� 靸侂嫶頃橃 鞎婌晿雼�瓿� 頇曥澑頄堨姷雼堧嫟.

韴瀽鞛� 彀戈碃 靷暛:

  • 鞚措矆 氤�瓴届潃 鞝堨皑鞝侅澑 靹标博鞙茧 氤挫澊氅�, 鞚搓铂鞚� 鞐嗠嫟電� 鞝愳潃 歃夑皝鞝侅澑 鞙勴棙 鞁犿樃毳� 雮顶雼堧嫟.
  • 1雲� 毵岇潣 臧愳偓鞚� 甑愳泊電� 韴瀽鞛愲摛鞚� 瓯半矂雱岇姢 鞐办啀靹标臣 頄ロ泟 臧愳偓 牍勳毄 霕愲姅 鞚检爼鞐� 雽�頃� 欤检嫓頃橁矊 頃� 靾� 鞛堨姷雼堧嫟.
  • 氤� 瓿奠嫓鞐愳劀電� 鞛 鞛瀾靹�, 鞝勲 氤�瓴�, 靾橃澋 雿办澊韯瓣皜 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Eton Pharmaceuticals, Inc. (NASDAQ : ETON) a d茅pos茅 un formulaire 8-K pour annoncer une transition d鈥檃uditeur effective au 13 juin 2025.

Renvoi de Crowe LLP : Le comit茅 d鈥檃udit a mis fin 脿 sa collaboration avec Crowe LLP apr猫s un seul cycle d鈥檃udit (exercice 2024). L鈥檕pinion de Crowe pour 2024 茅tait sans r茅serve (aucune opinion d茅favorable ou qualifi茅e), et la soci茅t茅 n鈥檃 signal茅 aucun d茅saccord ni 茅v茅nement 脿 d茅clarer avec la direction selon l鈥檃rticle 304(a)(1) du r猫glement S-K. La lettre de consentement requise de Crowe est jointe en annexe 16.1.

Nomination de Grant Thornton LLP : Le comit茅 d鈥檃udit a simultan茅ment engag茅 Grant Thornton LLP comme nouveau cabinet d鈥檃udit ind茅pendant pour l鈥檈xercice 2025. La soci茅t茅 confirme que, durant les exercices 2023, 2024 et la p茅riode int茅rimaire suivante, elle n鈥檃 pas consult茅 Grant Thornton sur des questions comptables ou d鈥櫭﹙entuelles opinions avant la nomination.

脌 retenir pour les investisseurs :

  • Ce changement semble de nature proc茅durale ; l鈥檃bsence de d茅saccords r茅duit le risque de signaux d鈥檃lerte imm茅diats.
  • Un changement d鈥檃uditeur apr猫s un an peut n茅anmoins inciter les investisseurs 脿 surveiller la continuit茅 de la gouvernance ainsi que les futurs frais ou d茅lais d鈥檃udit.
  • Aucune r茅vision financi猫re, changement de perspectives ou donn茅es de r茅sultats n鈥檃 茅t茅 divulgu茅 dans ce d茅p么t.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) hat ein Formular 8-K eingereicht, um einen Wechsel des Abschlusspr眉fers mit Wirkung zum 13. Juni 2025 bekannt zu geben.

K眉ndigung von Crowe LLP: Der Pr眉fungsausschuss hat Crowe LLP nach nur einem Pr眉fungszyklus (Gesch盲ftsjahr 2024) entlassen. Die Meinung von Crowe f眉r 2024 war 耻苍别颈苍驳别蝉肠丑谤盲苍办迟 (keine negativen oder eingeschr盲nkten Meinungen), und das Unternehmen berichtete unter Punkt 304(a)(1) der Regulation S-K keine Meinungsverschiedenheiten oder meldepflichtigen Ereignisse mit dem Management. Das erforderliche Einvernehmen von Crowe ist als Anlage 16.1 beigef眉gt.

Ernennung von Grant Thornton LLP: Der Pr眉fungsausschuss hat gleichzeitig Grant Thornton LLP als neue unabh盲ngige Wirtschaftspr眉fungsgesellschaft f眉r das Gesch盲ftsjahr 2025 beauftragt. Das Unternehmen best盲tigt, dass es im Gesch盲ftsjahr 2023, 2024 und im anschlie脽enden Zwischenzeitraum keine Beratung von Grant Thornton zu buchhalterischen Fragen oder m枚glichen Meinungen vor der Ernennung eingeholt hat.

F眉r Investoren wichtig:

  • Die 脛nderung erscheint prozedural; das Fehlen von Meinungsverschiedenheiten mindert unmittelbare Warnsignale.
  • Ein Wechsel des Abschlusspr眉fers nach einem Jahr k枚nnte Investoren dennoch dazu veranlassen, die Kontinuit盲t der Governance sowie k眉nftige Pr眉fungsgeb眉hren oder -fristen zu beobachten.
  • In dieser Meldung wurden keine finanziellen Neubewertungen, Prognose盲nderungen oder Gewinnzahlen offengelegt.

false 0001710340 0001710340 2025-06-13 2025-06-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
June 13, 2025
Date of Report (Date of earliest event reported)
 
 
ETON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38738
37-1858472
(State of
(Commission
(I.R.S. Employer
incorporation)
File Number)
Identification Number)
 
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7278
(Address of principal executive offices) (Zip code)
 
(847) 787-7361
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.001 per share
  
ETON
  
NASDAQ Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 4.01. Changes in Registrant’s Certifying Accountant.
 
(a) Dismissal of Previous Independent Registered Public Accounting Firm.
 
(i) On June 13, 2025, the Company dismissed Crowe LLP as the Company’s independent registered public accounting firm, effective June 13, 2025. The decision to terminate Crowe LLP as the Company’s independent registered public accounting firm was approved by the Company's Audit Committee (the “Audit Committee”) of the Board of Directors of the Company at a meeting held on June 13, 2025.
 
(ii) The Crowe LLP report on the Company’s financial statements for the year ended December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.
 
(iii) Crowe LLP was engaged by the Company on June 14, 2024, and served as the Company’s independent accountant for the fiscal year ended December 31, 2024. Crowe LLP did not audit the Company’s financial statements for any other fiscal year. From the date of Crowe LLP’s engagement, during the Company’s most recent fiscal year ended December 31, 2024 and the subsequent interim period through the date of this Current Report on Form 8-K, there were no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (“Regulation S-K”), and the related instructions thereto, with Crowe LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Crowe LLP, would have caused it to make reference to the subject matter of the disagreements in connection with its reports. Also, during this same period, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto.
 
(iv) The Company provided Crowe LLP with the disclosures under this Item 4.01(a) and requested Crowe LLP to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made by the Company in this Item 4.01(a) and, if not, stating the respects in which it does not agree. Crowe LLP’s letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.
 
(b) Appointment of New Independent Registered Public Accounting Firm.
 
(i) On June 13, 2025, the Audit Committee approved the appointment of Grant Thornton LLP (“Grant Thornton”) as the Company’s new independent registered public accounting firm for the Company's fiscal year ended December 31, 2025. The Company notified Grant Thornton on June 13, 2025, that it would be engaged as the Company’s independent registered public accounting firm.
 
(ii) During the fiscal years ended December 31, 2023 and 2024 and the subsequent interim period through the Date of this Report, neither the Company, nor anyone on its behalf, consulted Grant Thornton regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the financial statements of the Company, and neither a written report nor oral advice was provided to the Company that Grant Thornton concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).
 
2
 
 
Item 9.01: Financial Statements and Exhibits.
 
Exhibit No.
  
Description
     
Exhibit 16.1   Letter from Crowe LLP, dated June 20, 2025
Exhibit 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
3
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: June 20, 2025
By:
/s/ James R. Gruber
   
James R. Gruber
   
Chief Financial Officer and Secretary
   
(Principal Financial Officer)
 
4

Source:

FAQ

Why did ETON dismiss Crowe LLP as its auditor?

The filing states only that the Audit Committee decided on 13 June 2025 to dismiss Crowe LLP; no disagreements or adverse opinions were reported.

When does Grant Thornton鈥檚 engagement as ETON鈥檚 auditor begin?

Grant Thornton LLP was appointed on 13 June 2025 and will audit the fiscal year ending 31 December 2025.

Were there any accounting disagreements between ETON and Crowe LLP?

No. The company reports no disagreements on accounting principles, disclosures, or audit scope during Crowe鈥檚 tenure.

Does the 8-K include any financial restatements or earnings data?

No. The filing is limited to the auditor change and does not contain financial results or restatements.

Where can investors find Crowe LLP鈥檚 concurrence letter?

The letter is filed as Exhibit 16.1 to this Form 8-K, dated 20 June 2025.
Stock ETON logo
Eton Pharmaceuticals

NASDAQ:ETON

ETON Rankings

#4689 Ranked by Market Cap
N/A Ranked by Dividends
#76 Top Gainer

ETON Latest News

Jul 8, 2025
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Jun 27, 2025
Eton Pharmaceuticals Announces Addition to Russell 2000庐 and Russell 3000庐 Indexes
May 28, 2025
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI鈩� (hydrocortisone) Oral Solution
May 14, 2025
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
May 13, 2025
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

ETON Latest SEC Filings

Jul 8, 2025
[8-K] Eton Pharmaceutcials, Inc. Reports Material Event
Jun 27, 2025
[8-K] Eton Pharmaceutcials, Inc. Reports Material Event

ETON Stock Data

382.15M
25.66M
5.57%
49.37%
1.11%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
DEER PARK